Moleculin Biotech is trading 5.65% lower at $0.53 after opening-day weakness on September 23, 2026, with no clear explanation for the decline. - The company announced a Mexican patent covering lung-targeted liposomal Annamycin through November 23, 2040; this positive catalyst does not explain the drop. - Broader markets are weaker, while biotechnology is higher.